II
GLMD icon

Ibex Investors’s Galmed Pharmaceuticals GLMD Stock Holding History

Ibex Investors’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,856
Closed -$1.59M – 41
2021
Q4 		$1.59M Sell
4,856
-1,772
-27% -$800K 0.53% 25
2021
Q3 		$3.33M Sell
6,628
-154
-2% -$80.8K 0.7% 17
2021
Q2 		$3.71M Sell
6,782
-1,690
-20% -$919K 1.38% 8
2021
Q1 		$5.23M Hold
8,472
– – 1.8% 13
2020
Q4 		$4.74M Buy
8,472
+55
+0.7% +$34.3K 1.89% 11
2020
Q3 		$5.35M Buy
8,417
+2,945
+54% +$2.4M 2.82% 11
2020
Q2 		$4.71M Buy
5,472
+111
+2% +$93.6K 2.24% 14
2020
Q1 		$3.34M Buy
5,361
+53
+1% +$50.4K 3.36% 8
2019
Q4 		$5.52M Buy
5,308
+2
+0% +$1.72K 0.1% 10
2019
Q3 		$4.57M Buy
5,306
+820
+18% +$823K 0.29% 14
2019
Q2 		$5.93K Buy
4,486
+822
+22% +$1.06M 0.48% 17
2019
Q1 		$5.39M Buy
3,664
+886
+32% +$1.29M 0.48% 14
2018
Q4 		$3.42M Buy
2,778
+456
+20% +$796K 0.56% 17
2018
Q3 		$5.68M Buy
2,322
+439
+23% +$1.03M 3.15% 6
2018
Q2 		$4.03M Buy
1,883
+493
+35% +$714K 2.29% 12
2018
Q1 		$1.39M Buy
1,390
+129
+10% +$188K 1.15% 17
2017
Q4 		$2.08M Buy
+1,261
New +$1.86M 1.21% 11

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return

Ibex Investors's GLMD Position: Q1 2022 in Review

Ibex Investors sold out of Galmed Pharmaceuticals (GLMD) in Q1 2022, closing a stake of 4,856 shares — an estimated $1.59M sold.

Ibex Investors first reported a position in GLMD in Q4 2017 and held it in 17 quarters. The position peaked at $5.68M in Q3 2018. 23 funds tracked by Wall St. Rank hold GLMD as of Q1 2022.

  • Ibex Investors reported no remaining Galmed Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Ibex Investors sold 4,856 Galmed Pharmaceuticals shares in Q1 2022, an estimated $1.59M.
  • Ibex Investors first reported a position in Galmed Pharmaceuticals in Q4 2017 and held it in 17 quarters.
  • Ibex Investors's Galmed Pharmaceuticals position peaked at $5.68M in Q3 2018.
  • 23 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2022.

Based on Ibex Investors's 13F filing for Q1 2022, filed 29 Apr 2022.